Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate

The Journal of Urology
I M ThompsonF R Rodriguez

Abstract

Luteinizing hormone-releasing hormone agonist therapy for prostate cancer is a new method of management for metastatic disease. During the initial 1 to 2-week period of administration an increase in serum testosterone concentration can lead to an exacerbation of clinical symptoms (flare phenomenon). Two patients are summarized who received luteinizing hormone-releasing hormone agonist therapy without flare blockade and died suddenly during month 1 of therapy. A review of 765 patients in 9 series found 10.9% who suffered disease flare and 15 who died during disease flare. Of these 17 patients 12 were similar to our 2. These data suggest that any patient placed on luteinizing hormone-releasing hormone agonist therapy for prostate cancer merits some form of flare blockade during the initial 1 or 2 months of therapy.

Associated Clinical Trials

Oct 18, 2012·Karin Buchsteiner

References

Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Nov 15, 1984·The New England Journal of Medicine·UNKNOWN Leuprolide Study Group
Feb 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·T W ReddingA V Schally

❮ Previous
Next ❯

Citations

Oct 6, 2004·Expert Opinion on Pharmacotherapy·Pierre Mongiat-Artus, Pierre Teillac
Sep 1, 2009·Therapeutic Advances in Medical Oncology·Matthew A UhlmanLeon Sun
Jul 13, 2006·Pituitary·Anu DavisVictor Lavis
Apr 27, 2007·Current Urology Reports·Timothy C BrandIan M Thompson
Dec 4, 2009·Expert Review of Anticancer Therapy·Laurent Boccon-GibodBo-Eric Persson
Mar 9, 2011·Current Urology Reports·Mohamed IsmailLeonard G Gomella
Jun 1, 1993·British Journal of Urology·F H Schröder
May 31, 2002·Expert Opinion on Pharmacotherapy·Kris E Gaston, David K Ornstein
Jul 12, 2005·The Journal of Urology·Franklin D GaylisDaniel J Cosgrove
Oct 30, 2015·Expert Opinion on Drug Metabolism & Toxicology·Laurence Klotz
Jan 8, 2019·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·A YassinA Al Ansari
Jul 1, 1992·Postgraduate Medicine·E D Kemp
Apr 4, 2008·Asian Journal of Andrology·David J Handelsman, Alison Heather
May 27, 2008·British Journal of Pharmacology·D J Handelsman
Dec 14, 1991·BMJ : British Medical Journal·F H Schröder
Mar 26, 2005·Human Reproduction Update·F C H d'Ancona, F M J Debruyne
Apr 5, 2012·Current Opinion in Urology·Che-Kai TsaoWilliam K Oh
Mar 31, 2019·Molecular Cancer Therapeutics·Shaolin MaAnil K Sood
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rashid K SayyidNeil E Fleshner
Jun 10, 2021·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Satish Kumar Ranjan
Jun 1, 1996·Hematology/oncology Clinics of North America·M Robson, N Dawson
Sep 9, 2016·Journal of Medicinal Chemistry·Seon-Mi KimJeewoo Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.